anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed herein are methods and compositions suitable for the promotion of hair growth on humans and other animals. Disclosed embodiments include compositions comprising actin-binding peptides. In some embodiments, the actin- binding peptides comprise fragments of thymosin .beta.4. In other embodiments, the disclosure provides compositions comprising fragments of thymosin .beta.4 and/or other actin-binding peptides that are suitable for the treatment of alopecia and other conditions associated with hair loss. In still further embodiments, the disclosure provides compositions comprising the sequence of approximately six or seven amino acids of the thymosin .beta. 4 sequence that bind actin.
CNS stimulants, including methylphenidate hydrochloride, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usuallyintermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in postmarketing reports at different times and at therapeutic doses in all age groups throughoutthe course of treatment. Signs and symptomsgenerallyimprove after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.
BACKGROUND: The ongoing debate regarding the need for screening Cushing's syndrome (CS) in patients with obesity continues. The objectives of this study were to establish the prevalence of CS in the population with obesity and assess how metabolic health status influences cortisol levels following the 1 mg dexamethasone suppression test (DST).
METHODS: This retrospective study included 1008 patients with obesity who underwent screening with the 1 mg DST for CS. These patients were categorized into two groups as metabolically healthy obesity (MHO) and unhealthy obesity (MUO).
RESULTS: Out of the 1008 patients, 779 (77.3%) belonged to the MUO group. Within the entire study cohort, 12 (1.2%) patients exhibited a cortisol level of ≥ 1.8 after the 1 mg DST. Cortisol levels following the 1 mg DST were also significantly higher in the MUO group than in the MHO group (p = 0.001). Among these 12 patients, 11 were presenting a MUO phenotype. Hypercortisolism was definitively diagnosed in two patients, resulting in an overall prevalence of 0.2%. The 1 mg DST demonstrated a specificity of 99% and 100% sensitivity for screening for CS.
CONCLUSIONS: While the 1 mg DST is a practical screening test for CS with high specificity in obesity, the number of CS cases detected remains relatively low. Therefore, it may be more reasonable and applicable to screen patients with MUO phenotype rather than all individuals with obesity.
Severe neutropenia [absolute neutrophil count (ANC) <0.5 x 103/mcL] developed in up to 2% of renal, up to 2.8% of cardiac, and up to 3.6% of hepatic transplant patients receiving mycophenolate mofetil 3 g daily (see ADVERSE REACTIONS). Patients receiving mycophenolate mofetil should be monitored for neutropenia (see PRECAUTIONS: Laboratory Tests). The development of neutropenia may be related to mycophenolate mofetil itself, concomitant medications, viral infections, or some combination of these causes. If neutropenia develops (ANC <1.3 x 103/mcL), dosing with mycophenolate mofetil should be interrupted or the dose reduced, appropriate diagnostic tests performed, and the patient managed appropriately (see DOSAGE AND ADMINISTRATION). Neutropenia has been observed most frequently in the period from 31 to 180 days posttransplant in patients treated for prevention of renal, cardiac, and hepatic rejection. 

Patients receiving mycophenolate mofetil should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression.
Traditional Chinese acupuncture has a history of several thousand years. The World Health Organization has published guidelines describing the efficacy of acupuncture in the cure or relief of 64 different symptoms and conditions as one of the most representative intangible cultural heritage of humanity. However, for the need of patients and the gradual progress of technology, the applications of laser acupuncture become widespread. Laser acupuncture (LA) is not only applicated to stimuli specific areas in need, but also one of non-invasive intervention technic with hurtless intervention, no hematoma, bleeding or swelling unpleasant feeling after intervention, which could be more accepted by children, weakness people, and patients who afraid of acupuncture. To the area that traditional Chinese acupuncture could not stimuli easily of some area reflect to brain precisely, laser acupuncture is comparably convenient to supply adaptive energy input.

The goals of this study protocol is focus on the patients who accept total knee replacement (TKR), who usually suffer pain, swelling, or range of motion limitation after TKR surgery procedure, and the investigators want to use non-invasive LA to stimuli on 1) the reflection areas of ear acupuncture point associated knee and pain mechanism; 2) myofascial trigger points around knee joint, which may affect functional performance and prognosis after TKR procedure, with adequate frequency and energy power to stimuli, to observe the efficacy of LA on pain relief, swelling decline, and range of motion in knee joint improvement. One the one side, the investigators want to shorten the period of recovery, accelerate the function performance, and enhance the quality of life of patients after TKR procedure by LA intervention,on the other side, the investigators also want to confirm the value and curative effect of LA on clinical application and to evoke new idea for further development to traditional Chinese acupuncture.
Focal segmental glomerulosclerosis (FSGS) is a complex disease which describes different kinds of kidney defects, not exclusively linked with podocyte defects. Since nephrin mutation was first described in association with early-onset nephrotic syndrome (NS), many advancements have been made in understanding genetic patterns associated with FSGS. New genetic causes of FSGS have been discovered, displaying unexpected genotypes, and recognizing possible site of damage. Many recent large-scale sequencing analyses on patients affected by idiopathic chronic kidney disease (CKD), kidney failure (KF) of unknown origin, or classified as FSGS, have revealed collagen alpha IV genes, as one of the most frequent sites of pathogenic mutations. Also, recent interest in complex and systemic lysosomal storage diseases, such as Fabry disease, has highlighted GLA mutations as possible causes of FSGS. Tubulointerstitial disease, recently classified by KDIGO based on genetic subtypes, when associated with UMOD variants, may phenotypically gain FSGS features, as well as ciliopathy genes or others, otherwise leading to completely different phenotypes, but found carrying pathogenic variants with associated FSGS phenotype. Thus, glomerulosclerosis may conceal different heterogeneous conditions. When a kidney biopsy is performed, the principal objective is to provide an accurate diagnosis. The broad spectrum of phenotypic expression and genetic complexity is demonstrating that a combined path of management needs to be applied. Genetic investigation should not be reserved only to selected cases, but rather part of medical management, integrating with clinical and renal pathology records. FSGS heterogeneity should be interpreted as an interesting opportunity to discover new pathways of CKD, requiring prompt genotype-phenotype correlation. In this review, we aim to highlight how FSGS represents a peculiar kidney condition, demanding multidisciplinary management, and in which genetic analysis may solve some otherwise unrevealed idiopathic cases. Unfortunately there is not a uniform correlation between specific mutations and FSGS morphological classes, as the same variants may be identified in familial cases or sporadic FSGS/NS or manifest a variable spectrum of the same disease. These non-specific features make diagnosis challenging. The complexity of FSGS genotypes requires new directions. Old morphological classification does not provide much information about the responsible cause of disease and misdiagnoses may expose patients to immunosuppressive therapy side effects, mistaken genetic counseling, and misguided kidney transplant programs.
NEW MATERIAL:The compound of formulaI(X is O or S; R is halogen, hydroxy, lower alkyl or lower alkoxy). EXAMPLE:6,6a,7,8,9,10,10a,11-octahydro-11-oxodibenzo[b,e]thiepin. USE:Useful as a hypotensor or an intermediate of pharmaceuticals. Since the compound has two adjacent asymmetric carbon atoms (the C atoms at the 6a- and 10-positions), there are two kinds of trans-isomers and two kinds of cis- isomers. PROCESS:The compound of formulaIcan be prepared in the form of a mixture  of trans-isomer and cis-isomer, by cyclizing the compound of formula II (R<1> is halogen, lower alkyl, or lower alkoxy) in the presence of a condensation agent such as polyphosphoric acid, in a solvent such as benzene. The mixture can be separated into the trans-isomer and the cis-isomer by column chromatography, etc. The starting compound of formula II is novel, and can be prepared according to the reaction formula.
This invention discloses a composition comprised of nanoparticles having p-isononylphenoxypoly (glycidol) as a surface modifier adsorbed on the surface thereof. In preferred embodiments, the p-isononylphenoxypoly (glycidol) provides resistance to particle aggregation during heat sterilization. In another preferred embodiment, those nanoparticles also comprise a stability enhancing compound. A preferred stability enhancing compound is albumin. This invention further discloses a method of making nanoparticles having p-isononylphenoxypoly(glycidol) as a surface modifier adsorbed on the surface, comprised of contacting said nanoparticles with p-isononylphenoxypoly(glycidol) for a time and under conditions sufficient to form a p-isononylphenoxypoly(glycidol) surface modified nanoparticle. In a preferred embodiment, the p-isononylphenoxypoly (glycidol) surface modified nanoparticle is further contacted with a stability enhancing compound for a time and under conditions sufficient to form a p-isononylphenoxypoly(glycidol) surface modified nanoparticle with a stability enhancing compound associated therewith.
FIELD: pharmaceutical industry. SUBSTANCE: invention relates to methods of preparing of calcium gluconate of the increased solubility and decreased bacterial contamination that can be used for injection solutions preparing. Method involves treatment of calcium gluconate aqueous solutions with activated carbon, concentration, evaporation and crystallization under cooling. Crystals are separated and washed out and calcium gluconate aqueous solution is subjected for preliminary concentration before the stage of its treatment with activated carbon repeatedly. Crystallization is carried out from solutions of concentration 250-350 g/l up to decrease of concentration in solution below 150 g/l. Formed crystals are washed out with hydrogen peroxide solution cooled to 5-7 C either calcium gluconate aqueous solution is subjected for preliminary concentration before the stage of treatment with activated carbon followed by treatment with activated carbon again. Crystallization is carried out from solutions with concentration 150-250 g/l by addition of water-soluble organic solvent (50% by volume) before crystallization onset. Formed crystals are washed out with hydrogen peroxide solution cooled to 5-7 C. Invention provides preparing noncrystalline solutions corresponding to international standards. EFFECT: improved method of preparing, enhanced quality of product. 4 cl, 2 tbl, 3 ex
The first group is the study group. Patients aged 20 years or older and were to undergo suspension laryngoscopy procedure were eligible for inclusion in this group. Tongue areas were measured twice by submental USG. The first measurements (TA1) were done immediately after endotracheal intubation before introducing the rigid direct laryngoscope, whereas the second measurements (TA2) were done after the SL procedure and after removing the rigid direct laryngoscope just before extubation.The difference between TA2 and TA1 (i.e., TA2-TA1) were used to define the occurrence of tongue edema as study group.
An applicator for applying fibers to a surface is described herein. The applicator includes a body having a first end and a second end. The first end has a first opening configured to couple to a container housing the fibers and to receive the fibers from the container. The second end has a second opening for dispensing the fibers from the body. The applicator also includes an air flow generating member for creating an air current for propelling the fibers through the second opening as the fibres pass along a pathway between the first opening and the second opening. The fibers are directed along the pathway from the first opening towards the second opening and into the air current by gravity.
Peripheral nerve injury triggers rapid microglial activation, promoting M1 polarization within the spinal cord, which exacerbates the progression of neuropathic pain. C1q/TNF-related protein 9 (CTRP9), an adiponectin homolog, is known to suppress macrophage activation and exhibit anti-inflammatory properties through the activation of adiponectin receptor 1 (AdipoR1) in various disease contexts. Nevertheless, the involvement of CTRP9 in microglial polarization in the context of neuropathic pain is still unclear. Our study aimed to how CTRP9 influences spinal microglial polarization, neuroinflammation, and pain hypersensitivity, as well as the underlying mechanism, using a neuropathic pain model in male mice with spared nerve injury (SNI) of sciatic nerve. Our findings revealed SNI elevated the spinal CTRP9 and AdipoR1 levels in microglia. Furthermore, intrathecal administration of recombinant CTRP9 (rCTRP9) substantially weakened mechanical hypersensitivity and heat-related pain response triggered by SNI. On the other hand, rCTRP9 mediated a phenotypic switch in microglia, from the pro-inflammatory M1 state to the anti-inflammatory M2 state, by influencing the spinal AMPK/NF-κB mechanism in SNI mice. Additionally, treatment with AdipoR1 siRNA or an AMPK-specific antagonist both reversed the effects of CTRP9 on the phenotypic switching of spinal microglia and pain hypersensitivity. Collectively, these results indicate that CTRP9 ameliorates mechanical hypersensitivity and heat-related pain response, shifted the balance of microglia towards the anti-inflammatory M2 state, and suppresses neuroinflammatory responses by modulating the AMPK/NF-κB pathway, mediated by AdipoR1 activation, in mice with SNI.
Sarcopenia has a significant impact on falls, physical function, activities of daily living, and quality of life in older adults, and its prevention and treatment are becoming increasingly important as the global population ages. In addition to primary age-related sarcopenia, activity-related sarcopenia, disease-related sarcopenia, and nutrition-related sarcopenia have been proposed as secondary sarcopenia. Polypharmacy and potentially inappropriate medication based on multiple diseases cause health problems in older patients. In some cases, drugs used for therapeutic or preventive purposes act on skeletal muscle as adverse drug reactions and induce sarcopenia. Although sarcopenia caused by these adverse drug reactions may be more common in older patients, in particular those taking many medications, drug-related sarcopenia has not yet received much attention. This review summarizes drugs that may induce sarcopenia and emphasizes the importance of drug-related sarcopenia as a secondary sarcopenia. Geriatr Gerontol Int 2024; 24: 195-203.
PURPOSE:To improve the efficiency of medical clinic and research by means of a medical use picture by outputting an identification signal representing a picture element density of an output picture from each of plural medical use picture supply devices and varying the recording density according to the identification signal in a picture reproducing and recording device used in common. CONSTITUTION:A cord input device 23 is connected to a signal processing section 22 and receives a digital code signal E1 representing the picture element density therefrom. Code signals E1, E2 representing the picture element density of the picture carried in digital picture signals S2, S3 are added to the digital picture signals S2, S3 outputted from an X-ray CT device 2 and an ultrasonic diagnostic equipment 3. The picture signal S1, S2 or S3 is sent to a modulation circuit 38 and also fed to a control section 46 comprising a microcomputer or the like. Then the code signal E1, E2 or E3 added to the signal S1, S2 or S3 is read therein. The control section 46 outputs a subscanning speed command signal N in response to the code signals E1, E2, E3 and inputs them to a drive circuit 45.
The participants randomized to the Standard Care Physical Therapy group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of sessions will be 2-3 x per week for the initial 2 weeks, followed by 2 x per week until the culmination of physical therapy. The frequency and duration of sessions will be determined by the treating physical therapist based upon the clinical needs and progress of the specific participant.
The present invention provides methods of identifying a substance that down-regulates or up-regulates an immune response and kits used for the identification methods. A method of this invention comprises detecting a substance that inhibits or enhances the interaction between CD26 and caveolin-1. Another method comprises detecting a substance that inhibits or enhances the interaction between caveolin-1 and Tollip. Still another method comprises detecting a substance that inhibits or enhances the interaction among caveolin-1, Tollip, and IRAK-1. The present invention also relates to immunoregulatory agents comprising a substance that down-regulates an immune response, such as siRNA against caveolin-1 or Tollip. The invention further provides immunoregulatory agents comprising a substance that up-regulates an immune response. These agents are useful for treating inflammatory diseases, autoimmune diseases, or other immune-mediated disorders.
Sjögren's syndrome (SS) is a chronic, systemic and autoimmune disease characterized by inflammation, fibrosis, and dysfunction of exocrine glands such as tear and salivary glands. One of the most disturbing symptoms of SS is hyposalivation, xerostomia, and dysphagia due to the hypofunction of salivary glands. While xerostomia is the patient's subjective perception of dry mouth, hyposalivation is also evaluated objectively by salivary flow rate measurement methods (Pinto, 2021). Studies have reported that 0.9% to 64.8% of patients with SS experience xerostomia and 32% to 72% of them experience dysphagia (Orellana et al, 2016).

With the reduction of saliva, patients may experience difficulties in tasting, chewing, swallowing, speaking, and using prosthesis in patients using prostheses (Pinto, 2021). All these negatively affect the quality of life in patients with SS and their treatment is of great importance (Milin et al, 2016; Pinto, 2021). The treatment of dry mouth in patients with SS consists of pharmacological and non-pharmacological stimulation of the salivary glands and the use of artificial saliva preparations (Ramos_casals et al, 2020). Pharmacological methods used in patients with SS have been shown to reduce dry mouth, but these methods are mostly recommended in severe cases (Ramos_casals et al, 2020; Depinoy et al, 2021). In cases where pharmacological methods are not used, non-pharmacological methods such as taste stimulation (lozenge) and mechanical stimulation (gum) are also recommended in the control of dry mouth (Ramos_casals et al., 2020). It is known that chewing gum increases saliva secretion in studies conducted for different patient groups. used in the treatment of xerostomia in patients with SS, but no study has been found examining the relationship between chewing gum and salivation, xerostomia, and dysphagia in patients with SS (Ramos_casals et al, 2020). In the literature review, no study was found in which the effects of the tongue, lip, and jaw exercises on salivation, xerostomia, and dysphagia were evaluated in any patient group. This study was planned to examine the effects of chewing gum and tongue, lip, and jaw exercises on salivation, xerostomia, and dysphagia in patients with SS.
This research aims to characterize efficiency of a flexible ureteroscope that is of single use with regard to surgical time, absence of stone, and complications. From March 2022 to April 2023, the Basrah Urological Centre carried out this anticipated work. After excluding patients with untreated urinary tract infections, excessive blood urea, and ureteral strictures, the study involved ninety-eight patients. All patients were above 20 years of age. Patients were operated on by the same surgeon. This study involved 108 patients in this study composed of 42 (39.8%) men and 65 (60.2%) women. With a standard deviation of 10.9 years, the patient's mean age was 39.2 years. The total stone burden ranged from 6.9 to 14.5 mm, averaging 9.7±2.9 mm. The stone density ranged from 820-1411 HU, averaging 1000.8±279.3 HU. According to the current study, treating renal stones with a single-use flexible ureteroscope is less complicated and more successful.
A display having different segments that correspond to different categories of a care plan for a user may be provided. A dimension for the display segment is determined. The dimension indicates a relative importance of a care plan category that corresponds to the display segment compared to other care plan categories. A brightness is determined for the display segment based on the user's compliance with the care for the care plan category that corresponds to the display segment. The display segment is overlaid over at least a portion of a user-selected image for the display segment. A configuration of the overlay is based on the determined dimension and the determined brightness.
Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
Early marker-driven switch of anti-angiogenic agent and maintenance of chemotherapy: Bevacizumab and mFOLFOX6 will be administered until change of the CAF-profile and at least stable disease according to RECIST v1.1. Change to Aflibercept and mFOLFOX6 (change of bevacizumab to aflibercept and continuation of mFOLFOX6) until PD according to RECIST v1.1, followed by change to FOLFIRI after PD).
PURPOSE: A central control monitoring system and a monitoring method using the same are provided to efficiently check a patient state by integrally managing and monitoring various information from various medical devices in the central control monitoring system. CONSTITUTION: An information collecting unit collects general patient information, respirator information, defibrillation information, intravenous infusion monitor information, and nebulizer information. A monitor unit (100) displays the collected information. A monitoring unit (110) checks the abnormality of the collected information. A warning unit (120) makes a warning when a patient has abnormality. A recording unit (130) records the collected information. [Reference numerals] (110) Monitoring unit; (120) Warning unit; (130) Recording unit